← board
AVTX
Avalo Therapeutics, Inc.distress 8/10 · high distress / dilution risk$17.91-1%today-22% from 52w high
Immunology / Inflammation 1
Lead: hidradenitis suppurativa
Revenue
pre-revenue
Liquidity
$82M
Runway
1.4 yrs
Shares 1y
+300%
Price & events
+10.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
+0.2%
1W
+0.4%
1M
+21.4%
3M
+13.7%
6M
+168.5%
1Y
+45.4%
2Y
-99.8%
5Y
-99.8%
All
Overview
- Market Cap
- $941.45M
- Volume
- 29.51K
- 52 Week Range
- $4.78 – $22.87
- Total Shares
- 52.57M
- Float Shares
- 40.35M
- Short %
- 23.45%
- % Held by Insiders
- 1.73%
- % Held by Institutions
- 76.13%
- RVOL
- 0.02x
- Beta
- 0.79
Pipeline stages · 1 programs
AVTX-009 Regimen 1, AVTX-009 Regimen 2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-02-23 | Phase 2 | AVTX-009 Regimen 1, AVTX-009 Regimen 2 | Hidradenitis Suppurativa | 253 | completed |
Catalyst news & presentations · 5
- first half of 2027Guided 55%regulatory submissionFiled (NDA/BLA)AVTX-010 · IND submission planned.SEC 8-K
- 2026Guided 40%readoutPhase 2AVTX-009 · Topline data from Phase 2 LOTUS trial expected in 2026.SEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutPhase 2AVTX-009 · Topline data expectedSEC 8-K
- October 29, 2025enrollment completesecondaryPhase 2AVTX-009 · Completed enrollment in Phase 2 LOTUS trial with approximately 250 patients, exceeding target.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $45 (+150% upside) · 13 analysts
- 2026-07-06Leerink PartnersOutperform
- 2026-06-16BTIGBuy
- 2026-06-12B of A SecuritiesBuy
- 2026-05-14MizuhoOutperform
- 2026-05-14WedbushOutperform
- 2026-05-14HC Wainwright & Co.Buy
Competitors — hidradenitis suppurativa
Recent news
- 2026-07-22Avalo Therapeutics to Participate in the BTIG Biotechnology Conference - GlobeNewswire
- 2026-07-22Avalo Therapeutics to Participate in the BTIG Biotechnology Conference - GlobeNewswire
- 2026-07-22Avalo CEO to Participate in Virtual Hidradenitis Panel July 29 - Stock Titan
- 2026-07-18Form S-3 Avalo Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-18AVALO THERAPEUTICS INC (AVTX) Stock Chart - ChartMill
- 2026-07-17Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares - marketscreener.com
- 2026-07-17Avalo Therapeutics (NASDAQ: AVTX) files to register 128,189 shares for selling stockholders - Stock Titan
- 2026-07-15(AVTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.